Emergent BioSolutions (EBS) Return on Capital Employed (2011 - 2026)

Emergent BioSolutions' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 5.18% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 1279.0% year-over-year to 5.18% in Q1 2026; TTM through Mar 2026 was 5.18%, a 1279.0% increase from a year earlier, with the FY2025 full-year figure at 8.19%, up 1572.0% from the prior year.
• Return on Capital Employed slipped to 5.18% in Q1 2026 per EBS's latest filing, from 7.96% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 9.78% in Q1 2022 and bottomed at 60.19% in Q4 2023.
• The 5-year median for Return on Capital Employed is 8.55% (2024), against an average of 13.66%.
• Across the five-year window, Return on Capital Employed sank 6053 bps in 2023 and surged 5164 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 9.43% in 2022, then sank by 538 bps to 60.19% in 2023, then jumped by 86 bps to 8.55% in 2024, then jumped by 193 bps to 7.96% in 2025, then plunged by 35 bps to 5.18% in 2026.
• Per Business Quant, the three latest EBS Return on Capital Employed figures stand at 5.18% (Q1 2026), 7.96% (Q4 2025), and 9.1% (Q3 2025).